Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
- Anand, Aseem
- Morris, Michael J
- Larson, Steven M
- Minarik, David
- Josefsson, Andreas
- Helgstrand, John T
- Oturai, Peter S
- Edenbrandt, Lars
- Røder, Martin Andreas
- Bjartell, Anders
Publication date
March 2016
DOI Publisher
Springer Science and Business Media LLCAbstract
Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide
Add to ORKG